Document Detail

MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses.
MedLine Citation:
PMID:  19406868     Owner:  NLM     Status:  MEDLINE    
AIMS: To report the 4-month angiographic and 6-month clinical follow-up in first-in-man study using the tacrolimus-eluting bioabsorbable polymer-coated cobalt-chromium MAHOROBA stent. METHODS AND RESULTS: A total of 47 patients with either stable angina or unstable angina, or silent myocardial ischaemia, based on a de novo coronary stenosis that could be covered by a single 18 mm stent in a native coronary artery with a diameter between 3.0 and 3.5 mm were enrolled at three sites. The primary endpoint was in-stent late loss at 4 months. The secondary endpoints include %volume obstruction of the stents assessed by intravascular ultrasound (IVUS) at 4 months and major adverse cardiac events (MACE) at 6 months. Forty-seven patients were enrolled. Procedural success was achieved in 97.9%. At 4-month follow-up, in-stent late loss was 0.99 +/- 0.46 mm, whereas in-stent %volume obstruction in IVUS was 34.8 +/- 15.8%. At 6 months, there were no deaths, but 2 patients suffered from a myocardial infarction and 11 patients required ischaemia-driven repeat revascularization. The composite MACE rate was 23.4%. CONCLUSION: This tacrolimus-eluting stent failed to prevent neointimal hyperplasia, despite the theoretical advantages of the tacrolimus, which has less inhibitory effects on endothelial cells than smooth muscle cells.
Yoshinobu Onuma; Patrick Serruys; Peter den Heijer; Kaiyum Sheik Joesoef; Henricus Duckers; Evelyn Regar; Neville Kukreja; Shuzou Tanimoto; Hector M Garcia-Garcia; Heleen van Beusekom; Willem van der Giessen; Takuji Nishide
Related Documents :
8673748 - Coronary palmaz-schatz stent implantation in acute myocardial infarction.
17541138 - Old technique, new use: novel use of a buddy wire to deploy a detached stent.
10879618 - Local delivery of a low molecular weight heparin following stent implantation in the pi...
12641018 - Debulking prior to stenting--a worthwhile effort?
9117138 - Economic issues in coronary heart disease prevention.
6829788 - Pericardial superfusion to measure cardiac interstitial adenosine concentration.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2009-04-30
Journal Detail:
Title:  European heart journal     Volume:  30     ISSN:  1522-9645     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-15     Completed Date:  2009-07-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  1477-85     Citation Subset:  IM    
Thoraxcenter, Erasmus Medical Center, Ba-583, s-Gravendijkwal 230, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Absorbable Implants*
Angioplasty, Transluminal, Percutaneous Coronary / methods
Coronary Angiography
Coronary Stenosis / mortality,  therapy*
Drug-Eluting Stents / adverse effects*
Feasibility Studies
Hyperplasia / prevention & control
Immunosuppressive Agents / therapeutic use*
Middle Aged
Prospective Studies
Tacrolimus / therapeutic use*
Thrombosis / mortality,  prevention & control*
Time Factors
Treatment Outcome
Tunica Intima / pathology
Ultrasonography, Interventional
Reg. No./Substance:
0/Immunosuppressive Agents; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Exercise haemodynamic variables rather than ventilatory efficiency indexes contribute to risk assess...
Next Document:  Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks system...